CYENDIV (Nintedanib) belongs to the tyrosine inhibitor class drug that works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
It is used in the treatment of a patient suffering from metastatic advanced or locally recurring non-small cell lung carcinoma (NCLC) in combination with docetaxel.
And also together with other drugs for the treatment of Idiopathic Pulmonary Fibrosis(IPF). Nintedanib does not increase the survival rate in patients suffering from idiopathic pulmonary fibrosis, rather it is used in the proliferation differentiation and building extracellular matrix.